Targeting the alpha secretase ADAM10 for the treatment of Alzheimer's disease
靶向 α 分泌酶 ADAM10 治疗阿尔茨海默病
基本信息
- 批准号:10590899
- 负责人:
- 金额:$ 26.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-12-01 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAlzheimer&aposs disease therapeuticAmino AcidsAmyloid beta-ProteinAmyloid beta-Protein PrecursorBindingBiochemicalBiological AssayBiophysicsCell DeathCell LineCell surfaceCellsCognition DisordersColon CarcinomaComplexCryoelectron MicroscopyCysteineDegenerative DisorderDementiaDevelopmentDigestionDisadvantagedDisintegrinsEngineeringEphrinsEpidermal Growth Factor ReceptorEquilibriumExhibitsFamilyFree EnergyGlioblastomaHandHumanIn VitroKineticsLigandsLong-Term PotentiationMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMediatingMemoryMemory LossMetalloproteasesMolecularMolecular ConformationMolecular Mechanisms of ActionMonoclonal AntibodiesMusNamesNeuronsOncogenicPC12 CellsPathway interactionsPeptide HydrolasesPeptidesPositioning AttributePre-Clinical ModelPrevalencePrimary Bone OsteosarcomaPropertyProtease DomainProteinsProteolysisRattusReportingResearchResolutionSenile PlaquesSignal TransductionSpectrum AnalysisStructureSynapsesTertiary Protein StructureTherapeuticTherapeutic InterventionThermodynamicsToxic effectTransfectionUp-RegulationX-Ray CrystallographyZincalpha secretaseamyloid formationanalytical ultracentrifugationenthalpygamma secretasehuman monoclonal antibodiesimprovedmalignant stomach neoplasmmembermicrocalorimetrymouth squamous cell carcinomaneoplastic cellneuroblastoma cellneuroprotectionneurotoxicnotch proteinnovelnovel strategiesnovel therapeutic interventionoverexpressionprotein complexsecretasesequential proteolysisside effectstoichiometrytumor
项目摘要
Summary/Abstract
Alzheimer’s disease (AD), one of the most prevalent degenerative diseases, is characterized by
the prevalence of senile plaques that consist of fibrils of amyloid b (Ab). In the amyloidogenic pathway,
sequential proteolysis of the b-amyloid precursor protein (APP) by b and g secretases generate Ab (40-
42 amino acid) peptides. Ab multimerizes into neurotoxic oligomers that target the synapse, leading to
disruption of long-term potentiation, cell death, and memory loss. Alternatively, in the non-amyloidogenic
pathway, APP is cleaved sequentially by a and g secretase to generate sAPPa that exhibits
neuroprotective properties and precludes the formation of Ab. Studies have identified ADAM10, a
member of the adamlysin family of zinc metalloproteinases, as the constitutive a-secretase in neurons.
Activation of ADAM10 is currently being evaluated as a means of therapeutic intervention. However, this
strategy has severe disadvantages: ADAM10 is known to cleave multiple substrates and is upregulated
in a wide range of malignancies. A non-specific (non-selective) up-regulation/enhancement of ADAM10
as a means of therapeutic intervention in AD would likely have deleterious side effects. The importance
of the non-catalytic (disintegrin and cysteine rich) domains of ADAM10 in substrate recognition was
shown previously. A conformation specific mAb, 8C7, which recognizes an active conformation of
ADAM10 found on tumor cells was developed. Importantly, while 8C7 selectively enhances APP
cleavage in cell-based assay, it inhibits Notch-Delta and Eph-ephrin oncogenic signaling in preclinical
models, without any discernible toxicity effects in mice, thereby ruling out deleterious side effects that
might result from its potential use as AD therapeutic. The proposed studies will characterize the
ADAM10-APP interactions in vitro to better understand how the ADAM10 a-secretase interacts with and
cleaves APP. The molecular mechanism of action of the 8C7 mAb in promoting this cleavage will also
be investigated. A human version of the anti-ADAM10 mAb 8C7, named 1H5, that augments cleavage
of peptide substrates and binds to the substrate binding domain of ADAM10, was generated recently.
Similar to 8C7, this human mAb (1H5), as well as a single-chain variable fragment (scFv) derived from it,
will now be evaluated in cell-based assays in order to determine their efficacies in promoting APP
cleavage. The shedding of APP will further be examined in rat neuronal and human glioblastoma cell
lines in the presence of the mAbs (8C7 and 1H5) and the scFv. This proposal, to enhance the non-
amyloidogenic pathway with anti-ADAM10 mAbs towards the development of novel AD treatments,
serves as a proof of principle of therapeutic potential.
摘要/摘要
阿尔茨海默病(AD)是最常见的退行性疾病之一,其特点是
由淀粉样蛋白b(Ab)纤维组成的老年斑的患病率。在淀粉样蛋白生成途径中,
B和g分泌酶对b-淀粉样前体蛋白(APP)的顺序蛋白分解产生抗体(40-
42个氨基酸)。AB多聚体形成以突触为靶点的神经毒性低聚物,导致
长时程增强中断、细胞死亡和记忆丧失。或者,在非淀粉样变性患者中
途径,APP被a和g分泌酶顺序切割,产生SappA,展示
神经保护特性,并阻止抗体的形成。研究发现,ADAM10是一种
锌金属蛋白水解素家族的一员,作为神经元中的结构性α-分泌酶。
目前正在评估激活ADAM10作为一种治疗干预手段。不过,这个
该策略有严重的缺点:ADAM10已知可以裂解多种底物,并被上调
在一系列的恶性肿瘤中。非特异性(非选择性)上调/增强ADAM10
作为AD的一种治疗干预手段,可能会有有害的副作用。它的重要性
ADAM10的非催化(去整合素和富含半胱氨酸)结构域在底物识别中的作用
如前面所示。识别活性构象的构象特异性单抗8C7
发现肿瘤细胞上存在ADAM10。重要的是,虽然8C7选择性地增强了应用
在基于细胞的分析中,它抑制临床前的Notch-Delta和Eph-Ephin致癌信号
模型,在小鼠身上没有任何明显的毒性效应,从而排除了有害的副作用
可能是因为它可能被用作治疗AD的药物。拟议的研究将描述
ADAM10-APP在体外的相互作用以更好地了解ADAM10α-分泌酶如何与
裂解应用程序。8C7单抗促进这种切割的分子机制也将
被调查。一种人类版本的抗ADAM10单抗8C7,命名为1H5,可增强切割
ADAM10的底物结合域是最近产生的。
与8C7类似,该人源单抗(1H5)及其衍生的单链可变区(ScFv),
现在将在基于细胞的分析中进行评估,以确定它们在促进APP方面的有效性
乳沟。APP的脱落将在大鼠神经母细胞瘤和人脑胶质母细胞瘤细胞中进一步检测
在mAbs(8C7和1H5)和ScFv存在下的表达。这项建议,以加强非
抗ADAM10单抗的淀粉样变性通路有助于开发新的AD治疗方法,
作为治疗潜力原理的证明。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DIMITAR B NIKOLOV其他文献
DIMITAR B NIKOLOV的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DIMITAR B NIKOLOV', 18)}}的其他基金
Molecular mechanisms of Tie2/Angiopoietin signaling initiation
Tie2/血管生成素信号传导启动的分子机制
- 批准号:
9159077 - 财政年份:2016
- 资助金额:
$ 26.55万 - 项目类别:
Molecular mechanisms of Tie2/Angiopoietin signaling initiation
Tie2/血管生成素信号传导启动的分子机制
- 批准号:
9321086 - 财政年份:2016
- 资助金额:
$ 26.55万 - 项目类别:
Function-blocking anti-ADAM protease antibodies for inhibition of tumorigenesis
用于抑制肿瘤发生的功能阻断性抗 ADAM 蛋白酶抗体
- 批准号:
9024489 - 财政年份:2015
- 资助金额:
$ 26.55万 - 项目类别:
Function-blocking anti-ADAM protease antibodies for inhibition of tumorigenesis
用于抑制肿瘤发生的功能阻断性抗 ADAM 蛋白酶抗体
- 批准号:
8881452 - 财政年份:2015
- 资助金额:
$ 26.55万 - 项目类别:
STRUCTURAL STUDIES OF EPH RECEPTORS AND EPHRINS
EPH 受体和 EHRINS 的结构研究
- 批准号:
8361611 - 财政年份:2011
- 资助金额:
$ 26.55万 - 项目类别:
STRUCTURAL STUDIES OF EPH RECEPTORS AND EPHRINS
EPH 受体和 EHRINS 的结构研究
- 批准号:
8169221 - 财政年份:2010
- 资助金额:
$ 26.55万 - 项目类别:
SIGNAL TRANSDUCTION MECHANISMS OF CELL-SURFACE LIGAND-RECEPTOR SYSTEMS
细胞表面配体受体系统的信号转导机制
- 批准号:
7721231 - 财政年份:2008
- 资助金额:
$ 26.55万 - 项目类别:
DETERMINATION OF THE STRUCTURE OF APG7 BY MAD
MAD 测定 APG7 的结构
- 批准号:
7721329 - 财政年份:2008
- 资助金额:
$ 26.55万 - 项目类别:
Novel Small-Molecule Inhibitors of the Tie2/Angiopoietin Interactions and Signali
Tie2/血管生成素相互作用和信号的新型小分子抑制剂
- 批准号:
7426768 - 财政年份:2007
- 资助金额:
$ 26.55万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 26.55万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 26.55万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 26.55万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 26.55万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 26.55万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 26.55万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 26.55万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 26.55万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 26.55万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 26.55万 - 项目类别:














{{item.name}}会员




